


ADC

CMC

GLP

2023

32



Overview of the natural function of antibodies^[1]

B



10


Production route of hybridoma technology^[2]



VHH

VHH

ELISA









Nanobody production scheme using a phage display library^[3]

- 5-9


- B
- 1

- BCR
- 5-6


B





Nectin-4 Mouse Serum Titer



Nectin-4 (4-1) Sequencing (Top20)










Nectin-4 (4-6) Sequencing (Top20)






ADA







Raji cells were mixed with human PBMCs, and different doses of Rituximab was added to induce ADCC, the killing of raji cells were detected through FACS(CFSE labeling of raji).



Raji cells were mixed with human AB serum, and different doses of Rituximab was added to induce CDC, the killing of raji cells were detected through FACS(PI staining of raji).




B cells were treated with Telitacept and induced with Baff for 72 hours, H3-thymidine incorporation were analyzed through scintillation counting.



T cells were treated with compound A and induced with ICOSL for 72 hours, H3-thymidine incorporation were analyzed through scintillation counting.



- A/IgG1 CD3/LPS PBMC 25
Luminex TNFα .
- ICH IL-6 IL-10 IFN-γ TNF-α PBMC IL-2
3 ELISA Luminex CBA
MSD OKT3
-



LQ036

20222

LQ036LQ036

IL-4Rα

() IND

CDE

LQ036

LQ036

LQ036

NMPA

TGA

AAALAC


GLP-like

AAALAC

GLP-like

- /
-

: CD3+ Bispecific Antibody



- Animals:**
Female NOG mice
- Tumor Cells:**
Tumor mixed hPBMC (1:1) with 50% Matrigel, SC
- PBMC:**
injected before tumor cells inoculation
- Treatment:**
Bispecific antibody

Vehicle	1639.53	/	/
Antibody	340.90	90.38	<0.001

/

PK

: Pharmacokinetics of YYB-101 in cynomolgus monkeys

YYB-101

10 mg/kg

T_{max}

YYB-101	50mg/kg	29	85
1			
	I		
			(NCT02499224)

Toxicokinetic parameters on days 1 and 22 following intravenous infusion of YYB-101 at 10, 50, or 200 mg/kg perday in cynomolgus monkeys^[4]

BAT6021

BAT6005

20219

BAT6021

BAT6005

BAT6021

BAT6005

TIGIT

BAT6021

BAT6005

BAT7104

202110

PD-L1/CD47

BAT7104

BAT7104

PD-L1/CD47

PD-1/PD-L1

CD47/SIRP- α

BAT7104

BAT7104

GLP

BAT7104

JYB1904

20225

JYB1904

GLP

JYB1904

JYB1904

JYB1904

IgE

JYB1904

IgE

CC312

20226

CD28

CD19/CD3/CD28

CC312

IND

FDA

CC312

CC312

GLP

GT90008

202210

TGF- β R2

PD-L1/TGF- β

(GT90008)

GT90008

PD-L1/TGF- β

PD-L1

GT90008

GLP

/

HCW9218

2022 10 HCW Biologics Inc. HCW9218 FDA HCW9218
 TGF- β II IL-15/IL-15 α NK CD8⁺ T
 HCW HCW GLP
 HCW9218
 SEND HCW9218 FDA

NB002

2023 7 NB002 FDA NB002 TIM-3
 T NK NB002
 DC TIM-3
 FDA NB002 IND

:

- [1] Ivana Spasevska. An outlook on bispecific antibodies: Methods of production and therapeutic benefits.
- [2] Abdullah F U H Saeed, et al. Antibody Engineering for Pursuing a Healthier Future. Front Microbiol. 2017 Mar 28;8:495. doi: 10.3389/fmicb.2017.00495.
- [3] MA Lin-lin, et al. Construction and screening of phage display library for TIM-3 nanobody. Acta Pharmaceutica Sinica 2018, 53 (3): 388-395.
- [4] Hyori Kim, et al. Preclinical development of a humanized neutralizing antibody targeting HGF. Exp Mol Med. 2017 Mar 24;49(3):e309. doi: 10.1038/emm.2017.21.



MEDICILON

Email: marketing@medicilon.com

Address: 50 Soldiers Field Place, Boston, MA 02135

Website: www.medicilon.com Tel: +1(626)986-9880